504433-24-3 Usage
Uses
Used in Pharmaceutical Industry:
GW441756 hydrochloride is used as a potential therapeutic agent for the treatment of various pain conditions and inflammatory diseases. Its high selectivity and unique mechanism of action make it a valuable tool for researchers studying the TRPV1 receptor and its role in pain and inflammation pathways.
Used in Chronic Pain Treatment:
GW441756 hydrochloride is used as a potential treatment for chronic pain, as it can effectively reduce pain and inflammation by blocking the TRPV1 receptor. This makes it a promising candidate for the development of new analgesic drugs.
Used in Neuropathic Pain Treatment:
GW441756 hydrochloride is used as a potential treatment for neuropathic pain, a type of pain caused by damage to the nervous system. Its ability to block the TRPV1 receptor can help alleviate the pain associated with this condition.
Used in Inflammatory Disease Treatment:
GW441756 hydrochloride is used as a potential treatment for inflammatory diseases, as its ability to block the TRPV1 receptor can help reduce inflammation and alleviate symptoms associated with these conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 504433-24-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,0,4,4,3 and 3 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 504433-24:
(8*5)+(7*0)+(6*4)+(5*4)+(4*3)+(3*3)+(2*2)+(1*4)=113
113 % 10 = 3
So 504433-24-3 is a valid CAS Registry Number.
504433-24-3Relevant academic research and scientific papers
Tandem Horner-Wadsworth-Emmons/Heck procedures for the preparation of 3-alkenyl-oxindoles: The synthesis of Semaxanib and GW441756
Lubkoll, Jana,Millemaggi, Alessia,Perry, Alexis,Taylor, Richard J.K.
experimental part, p. 6606 - 6612 (2010/10/19)
A tandem sequence involving Horner-Wadsworth-Emmons (HWE) olefination followed by a palladium-catalysed intramolecular Heck reaction has been developed to provide rapid access to 3-alkenyl-oxindoles from α-halo-anilides. This one-pot microwave accelerated process proceeds with catalytic palladium(II) acetate or tetrakis(triphenylphosphine)palladium, and has been used to prepare a range of adducts derived from aromatic, heteroaromatic and aliphatic aldehydes. The procedures can be used to prepare N-unprotected oxindoles directly and the applicability of the process has been established by carrying out one-pot syntheses of Semaxanib, an angiogenesis signalling inhibitor, and GW441756, an aza-oxindole Trk A inhibitor.
